Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,117.91
(
-0.28%
)
US TECH 100
26,104.00
(
-0.38%
)
Dow Jones
49,350.07
(
-0.28%
)
Brent Oil
100.59
(
4.00%
)
Bitcoin
77,924.68
(
-0.40%
)
News Focus
News Focus
Post# of 257439
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

p3analyze

Send PM Follow Ignore
Followers 9
Posts 957
Boards Moderated 0
Alias Born 07/16/2006

p3analyze

Re: DewDiligence post# 49931

Friday, 07/20/2007 1:48:31 PM

Friday, July 20, 2007 1:48:31 PM

Post# of 257439
Has DMC mandated cross-over after the interim analysis? I noticed FDA presented the hazard ratio of 0.9 with footnote that was when placebo patients were not crossed over to Satraplatin. If cross-over did happen, then it's a blessing - just the way it did for panitumumab, wouldn't you say?
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today